Micro innovations

Article

In technological terms, when a word is prefixed by 'micro' you come to expect that word to signify some form of technological innovation or advance. In ophthalmology, the word 'microincision' represents significant advancement, particularly in the fields of cataract and vitreoretinal surgery.

Some believe not. In this issue, we hear from several surgeons who have been so impressed by the results that they have witnessed with the new generation of lenses that they felt compelled to tell us about it. Take a look at our feature section on microincision IOLs and see what you think. Is it all hype or are we witnessing the next stage in the evolution of cataract surgery?

On another note, OTE recently launched its weekly subspecialty newsletters, covering cataract & refractive, retina and glaucoma. If you haven't subscribed to these weekly eNews alerts yet, what are you waiting for? Simply go to http://www.oteurope.com/ to sign-up. It's a great way of keeping you up-to-date with what's going on in your field. If you do already receive them, please feel free to let me know what you think of them. Is there anything else you'd like to see or (finger's crossed) are they perfect as they are? Either way, I'd love to hear from you.

Fedra PavlouEditorfpavlou@advanstar.com

Dear Editor,

I read your 'From the Editor' titled "LASIK: some still in the dark" (Ophthalmology Times Europe, Jan/Feb 2008) with great interest.

You are perfectly right - there are some specialists in clinics who do not provide enough information to their cases!

But there is another problem that you didn't mention. Thousands of cases of iatrogenic keratectasy have been reported in the United States following refractive surgery. Indeed, LASIK partly mimics the genetic characteristics of keratoconus where continuous intraocular pressure begins to deform the central cornea after a number of years or decades. In the long run, this could lead to a greater number of people requiring a perforating corneal graft, which even these days is sometimes difficult to perform because of the lack of available donor material.

This problem has been discussed in the United States during recent years, because of the increasing number of cases. I believe that this condition is deserving of discussion in Europe too because it is a problem that we must all consider.

Sincerely yours, Prof. Dr. J. DraegerUniversitäts-AugenklinikHamburg, Germany

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.